We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Immunochromatographic Strip Endorsed for α-Thalassemia Screening

By LabMedica International staff writers
Posted on 19 Nov 2014
Print article
Image: Immunochromatographic strip test for Hb Bart’s in blood samples of α0-thalassemia heterozygote and individuals double heterozygous for homozygous Hb E and α0-thalassemia and α0β-thalassemia double heterozygote (Photo courtesy of Mahidol University).
Image: Immunochromatographic strip test for Hb Bart’s in blood samples of α0-thalassemia heterozygote and individuals double heterozygous for homozygous Hb E and α0-thalassemia and α0β-thalassemia double heterozygote (Photo courtesy of Mahidol University).
Image: Inclusion body positive cells seen in Brilliant Cresyl Blue stained red cells of a α0-thalassaemia carrier (Photo courtesy of American Society of Hematology).
Image: Inclusion body positive cells seen in Brilliant Cresyl Blue stained red cells of a α0-thalassaemia carrier (Photo courtesy of American Society of Hematology).
Thalassemia is an autosomal recessive inherited genetic disorder of the red blood cells causing by reduction or absence of one or more globin chains of hemoglobin (Hb) molecules.

An immunochromatographic (IC) strip test has been developed for rapid screening of α0-thalassemia by testing for Hb Bart’s in blood samples using a specific monoclonal antibody against Hb Bart's.

Molecular Bioscientists at the Mahidol University, Nakhonpathom, Thailand) working with their Australian colleagues, collected a total of 662 routinely leftover anticoagulated blood samples, 411 from Thailand and 251from West Australia and included in a multicenter study. Hematologic data were determined by the automatic blood cell counters being operated at individuals laboratory collaborated in this multicenter study.

Polymerase chain reaction (PCR) was used to identify α0-thalassemia, α+-thalassemia, Hb H disease and non-deletion α-thalassemia in most samples. In two laboratories α-thalassemias were detected by the presence of erythrocyte Hb H inclusion bodies using the enriched young red cells from just below the buffy coat. A modified Alpha Thal IC strip test (i+MED Laboratories, Bangkok, Thailand) for screening of α-thalassemia was also tested.

There were 45 samples with α-thalassemia traits and were demonstrated to have the α0-thalassemia gene, 18 were from Hb H and EA Bart’s disease patients and 15 were homozygous α+-thalassemia or compound heterozygous α+-thalassemia and non-deletion α-thalassemia. All of these samples showed strongly positive results with IC strip test except for two α0-thalassemia samples, which had the negative results and were accounted for as false negatives. Among the 180 samples with normal α-globin genotyping the IC strip test revealed 97.8% negative reactivity.

The authors concluded that in combination with red blood cell indices, the IC strip test could rule out mass populations for further α0-thalassemia detection by PCR-based analysis. The established IC strip test has an advantage since it does not require sophisticated equipment, easy to perform and the result can be visually interpreted without an expert. It is also less-time consuming and can be done with a large number of samples, and therefore the IC strip test can be applied in thalassemia screening program, which will reduce the need of expensive PCR methods in the inappropriate cases for diagnosis of α0-thalassemia carriers. The study was published on November 6, 2014, in the journal Translational Research.

Related Links:

Mahidol University
i+MED Laboratories


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
H.pylori Test
Humasis H.pylori Card

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.